The primary aim of this Phase I study is to evaluate the pharmacological dose-related effects of a newly developed contrast agent for use with MRI. Agents currently being used are available in doses of 0.1 to 0.3 mmol/kg. This new agent is a non-ionic, extracellular, linear gadolinium based chelate that will be tested in doses of 0.1, 0.3, and 0.5 mmol/kg. Subjects will be patients with known brain, spine, and/or liver disease, and were chosen to be representative of the type of patient for which contrast MRI is currently being used. This study was completed in September, 1997.
Showing the most recent 10 out of 396 publications